Monthly Archives: September 2012

NICE: What the New Compliance Regime Will Mean for Pharma

By Guest Blogger | Published: September 21, 2012
By Martin Smith and Tim Suter. A recent decision by the Department of Health (DoH) to introduce a compliance regime for NICE (National Institute for Health and Clinical Excellence) technology appraisals will open the door to ensuring better implementation by NHS Trusts and Joint Prescribing Groups of NICE guidance. Importantly, the regime will also open new avenues [...]
Posted in Global, Guest Blog, Regulatory | Tagged , , , , | Leave a comment

Pharm Exec's 11th Annual Industry Audit: A Snapshot

By Guest Blogger | Published: September 18, 2012
Compiled by Bill Trombetta, Professor of Pharmaceutical & Healthcare Marketing at St. Joseph University, Pharm Exec’s 11th Annual Industry aims to provide a snapshot of how well companies are doing in advancing shareholder value. Pharm Exec’s 2012 Industry Audit relies on 2011 data to compare performance against 2010. As in years past, we use eight metrics [...]
Posted in Guest Blog, Sales, Strategy | Tagged , , , , | Leave a comment

Customer Engagement: Can Technology Help Find That Sweet Spot?

By William Looney | Published: September 17, 2012
In the rush toward customer engagement, can technology find the sweet spot? Cegedim Relationship Management held its annual conference on trends in the life sciences industry last week, with two days of speakers and workshops focused on the interrelated themes of Transformation and Innovation.  The central question: if the business of pharma is changing at warp [...]
Posted in Events, Patient Communication, Sales, Technology, healthcare | Tagged , , , , | 2 Comments

Sanofi's Aubagio to Square Off Against MS Injectables

By Ben Comer | Published: September 13, 2012
The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya, and Biogen Idec’s hotly anticipated BG-12, which has a PDUFA date scheduled for December 28. Both Gilenya and BG-12 are administered orally as opposed to injected, but execs at Genzyme – [...]
Posted in FDA, Regulatory, Safety, Strategy, pricing | Tagged , , , , | 2 Comments

Working Out the Kinks in Health IT

By Ben Comer | Published: September 12, 2012
Industry executives and government officials convened in Washington DC yesterday to examine the present state of health information technology (HIT), and to identify the bugs, challenges and hiccups that continue to plague EHR platforms, and the policies that regulate them.
Posted in E-Media, Regulatory, Safety, Technology | Tagged , , , , , | Leave a comment